中國旭陽(01907.HK):爭取5年內焦炭業務量提升至3,000萬噸
中國旭陽(01907.HK)主席兼行政總裁楊雪崗表示,未來5年目標將主要焦炭業務量擴張到3,000萬噸,同時繼續拓展焦化企業運營管理業務,提高市場佔有率及議價能力。
上半年公司純利按年減少58.3%,主要由於2月至4月焦炭產品價格下跌,導致價差收窄。市場管理部副總經理高新奇解釋,7月市場出現供不應求情況,目前價格已有所回升,預料明年內地基建推動需求上升,加上全國去產能下供應減少,預期價格將自今年第四季價格起繼續穩中有升。
今年上半年旭陽資本開支達約12.8億元人民幣(下同),當中有約10億元用於3個固定資產項目的工程,料下半年再需要投入約10億元。他強調經營現金流可覆蓋,亦會尋找長期項目貸款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.